Skip to content
    TMDX
    Earnings call· Jun 2026(Q2 FY26)

    TransMedics Group Q2 FY26 earnings call TMDX

    Aug 4, 2026 Source

    Executive summary

    TransMedics Q2 FY26 — Record Revenue and Strategic Growth Investments

    TransMedics delivered record Q2 FY26 revenue, driven by strong OCS case volume and clinical services, particularly in logistics. The company is aggressively investing in four strategic growth initiatives—heart/lung expansion, OCS Kidney development, European market entry, and the next-gen OCS platform—to achieve over $2 billion in annual revenue by 2032, prioritizing long-term growth over near-term operating leverage.

    Highlights

    5

    • Total revenue reached approximately $190 million, marking the highest quarterly revenue in history, up 21% year-over-year and 9% sequentially.

    • Service revenue grew approximately 29% year-over-year to $79 million, driven by market share gains in logistics and improved operating efficiency.

    • Adjusted income from operations was approximately $25.8 million, representing a 14% operating margin, while continuing to fund growth initiatives.

    • The company ended the quarter with approximately $473 million in cash and cash equivalents, providing confidence in self-funding growth investments.

    • The low end of full-year 2026 revenue guidance was raised to a range of $737 million to $757 million, representing 22% to 25% growth over 2025.

    Concerns

    4

    • Full-year adjusted operating margin guidance (excluding PAD Aviation) was lowered to 12.5% to 14% (from a prior expectation of 16%), reflecting higher planned investment in OCS Kidney.

    • The initial consolidation of PAD Aviation is expected to be dilutive to both gross margin and operating margin beginning in the third quarter.

    • ENHANCE Part B and DENOVO clinical programs experienced delays in IDE approval, resulting in minimal contribution to Q2 results.

    • Total gross margin declined approximately 180 basis points year-over-year, primarily due to a higher mix of service revenue and temporary product cost pressures.

    Guidance & targets

    15
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $737 million to $757 million
    high materiality
    High
    Full-year 2026 Adjusted Operating Margin (excluding PAD Aviation)
    approximately 12.5% to 14%
    high materiality
    Medium
    Full-year 2026 Gross Margin (excluding PAD Aviation)
    approximately 59%
    medium materiality
    Medium
    Long-term Gross Margin
    approximately 60%
    medium materiality
    Medium
    Transplants Supported by TransMedics Platform
    approximately 30,000
    high materiality
    High
    Annual Revenue
    more than $2 billion
    high materiality
    High
    OCS Kidney First Clinical Experience
    later in 2027
    high materiality
    Medium
    Italy National Reimbursement for Machine Perfusion and Services
    take effect later this year or early 2027
    medium materiality
    Medium
    ENHANCE Part B IDE Supplement Approval
    late Q3 or early fourth quarter
    high materiality
    Medium
    Lung IDE Approval
    shortly thereafter
    medium materiality
    Medium
    ENHANCE Part A Completion
    before year-end
    medium materiality
    High
    Full-year 2026 Headquarter-related Interest Expense
    $15.3 million
    low materiality
    High
    Full-year 2026 Total Interest Expense
    approximately $29 million
    low materiality
    High
    Full-year 2026 Interest Income
    approximately $12 million
    low materiality
    High
    Full-year 2026 Effective Tax Rate
    approximately 26%
    low materiality
    High

    Segment performance

    9
    SegmentRevenueYoYQoQMargin
    Total Company
    Highest quarterly revenue in company history.
    		$190M21%9%—
    U.S. Transplant
    Strong growth across OCS case volume and clinical services.
    		$184M21%10%—
    International
    Reflects continued progress in expanding European presence; early innings of growth story with expected quarterly variability.
    		$5M26%——
    Transplant Product
    Growth led by liver.
    		$111M16%3%—
    Service
    Increase primarily driven by broader adoption of TransMedics Logistics and pricing adjustments. Service margin improved from 27% in Q1 FY26 to 35% in Q2 FY26 due to higher fleet utilization, improved operating efficiency, and optimization.
    Service revenue as % of total revenue: 41%
    		$79M29%19%35%
    Liver
    Led overall growth.
    		$148M28%7%—
    Heart
    Expected to accelerate in Q4 and beyond with ENHANCE Part B.
    		$33M6%23%—
    Lung
    Minimal contribution from DENOVO clinical program.
    		$2M———
    TransMedics Logistics
    Clear evidence of vertical integration as a growth engine and structural differentiator. Improved operating efficiency.
    NOP mission requiring air transport coverage: 86% (up from 82% in Q1)
    		$41M39%30%—

    Operational metrics

    22
    Adjusted Income from Operations
    $25.8M
    Q2 FY26

    Delivered while continuing to fund growth initiatives.

    Cash and Cash Equivalents
    $473M
    Q2 FY26

    Gives confidence in ability to self-fund growth investment.

    Restricted Cash
    $18M
    Q2 FY26

    Primarily related to headquarters' lease.

    Adjusted Operating Expenses
    $87Mup 46% YoY, up 5% QoQ
    Q2 FY26

    Reflects increased investment in R&D and infrastructure for future growth. Excluding strategic growth programs, operating expenses declined sequentially.

    Adjusted R&D
    $32Mup 99% YoY
    Q2 FY26

    Primarily driven by investment in strategic growth programs.

    Adjusted SG&A
    $55.8Mup 27% YoY, down 4% QoQ
    Q2 FY26

    Year-over-year increase reflects Somerville headquarters, NOP network, IT infrastructure, and international expansion. Sequential decline due to nonrecurring payroll-related costs and decreased consulting spending.

    Interest Expense
    $7.2M
    Q2 FY26

    Includes finance lease for new Somerville headquarters.

    Adjusted Net Income
    $16.2M
    Q2 FY26

    Non-GAAP measure.

    Adjusted Diluted EPS
    $0.44
    Q2 FY26

    Non-GAAP measure.

    Diluted Weighted Average Shares
    40.7M
    Q2 FY26

    For diluted EPS calculation.

    Effective Tax Rate
    24.3%
    Q2 FY26

    For the quarter.

    Service Gross Margin
    35%up from 27% in Q1 FY26
    Q2 FY26

    Reflecting higher fleet utilization, improved operating efficiency, and continued optimization of service offerings.

    Product Gross Margin
    77%stable sequentially
    Q2 FY26

    Broadly stable sequentially.

    Estimated Incremental U.S. Heart and Lung Cases (ENHANCE/DENOVO)
    2,000 to 5,000
    annually

    Conservatively estimated additional addressable opportunity from existing product line.

    U.S. Deceased Kidney Transplants
    more than 21,000
    annually

    Largest transplant market segment.

    Recovered Deceased Donor Kidneys Never Transplanted
    approximately 9,200
    2024

    Largely due to limitations of cold storage preservation.

    Patients on U.S. Kidney Waiting List
    approximately 100,000
    any given time

    Significant demand for better donor kidney utilization.

    New ESRD Cases Diagnosed
    more than 131,000
    each year

    Indicates ongoing demand for kidney treatment.

    Estimated CMS Cost of Kidney Waiting List
    approximately $10 billion
    annually

    Highlights the national interest in improving kidney utilization.

    Delayed Graft Function (DGF) Incidence
    26% to 50%
    post-transplant

    Requires patients to return to dialysis at significant cost and morbidity.

    Incremental Cost per DGF Case
    approximately $25,000 to $45,000
    per case

    Associated with delayed graft function post-kidney transplant.

    Annualized Revenue Run Rate
    approximately $800M
    current

    Current run rate with substantial growth initiatives still ahead.

    Industry KPIs

    9
    MetricValueDetails
    System utilizationapproximately 86%%
    Pricing realized pricepricing adjustments
    New product launch rampminimal contribution
    Procedure volume growthGrowth was led by liver; Heart also grew
    FCF conversion leverage guidance12.5% to 14%%
    Segment franchise organic growthLiver up approximately 28% year-over-year; Heart grew approximately 6% year-over-year%
    Consumables recurring revenue mix41%%
    Indicated addressable patient populationapproximately 2,200transplants
    Pivotal trial clinical evidence milestonesIDE supplement submitted and under FDA review

    Product announcements

    1
    ProductTypeDetails
    Donor and Recipient Clinical Screening Coordination Serviceslaunch

    Deals & partnerships

    1
    PAD AviationStrategic investment to establish TransMedics Aviation Europe and build a pan-European transplant logistics network.

    PAD Aviation is located in Paderborn, Germany, providing a central location for accessing European countries. The acquisition provides the license to operate in Europe, access to a large number of pilots, and a sizable fleet. The plan is to transition PAD's existing third-party charter business into 100% transplant operations over time as demand ramps up.

    Risks & headwinds

    5
    Operating margin dilution from strategic investmentsFY26

    Full-year 2026 adjusted operating margin guidance lowered to 12.5% to 14% (from 16%)

    Mitigation: Deliberate acceleration of key strategic growth programs (e.g., OCS Kidney) for long-term value creation, not broad-based overhead expansion.

    Dilutive impact from PAD Aviation acquisitionBeginning Q3 FY26

    Initial consolidation will be dilutive to both gross margin and operating margin

    Mitigation: Expects financial profile to improve over time as the business is integrated and utilization for transplant missions increases.

    Delays in clinical trial approvalsQ2 FY26, ongoing

    Minimal contribution from ENHANCE Part B or DENOVO clinical programs in Q2

    Mitigation: Working collaboratively with FDA; IDE supplement for ENHANCE Part B expected late Q3/early Q4, Lung IDE to follow shortly. Focus on rapid adoption post-approval.

    Gross margin pressureQ2 FY26

    Down approximately 180 basis points year-over-year

    Mitigation: Primarily reflects higher mix of service revenue and temporary product cost pressures (inventory provisioning, trial-related solution costs), partially offset by improved logistics performance and operating efficiencies. Expects some normalization in service margin in H2.

    Seasonal softness in transplant procedure volumeQ3 FY26

    Q3 is traditionally a seasonally soft quarter

    Mitigation: Acknowledged by management, with caution regarding August trends. Company focuses on driving its own adoption and market share.

    What to watch in Q3 FY26

    5

    ENHANCE Part B IDE Supplement Approval

    late Q3 or early Q4
    CurrentUnder FDA review
    TargetApproval by late Q3 or early Q4

    Why it matters

    This approval is critical for unlocking the ENHANCE Part B trial, which targets a significant U.S. heart segment and is a key driver for future growth.

    We expect it to be approved by late Q3 or early fourth quarter, with the lung IDE to follow shortly thereafter.

    Q&A highlights

    8

    What drove the strong increase in service revenues, outpacing disposables, and were dry runs a factor?

    Waleed Hassanein clarified that there was no increase in dry run rates. He attributed the service revenue growth to gaining market share in logistics, improved operating efficiency, pricing adjustments to offset higher costs, and the addition of new centers.

    “Gaining market share in logistics, gaining a lot of efficiency in our logistics, improving our margins, pricing adjustment to buffer against the increase in costs, new centers. So that's -- these all combined lead to that picture.”

    asked by K. Gong · answered by Waleed Hassanein

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Platform and Moat

    TransMedics has developed a first-in-class, vertically integrated organ transplant platform comprising four distinct assets: the Organ Care System (OCS) technology, the National OCS Program (NOP), the Transplant Logistics Network, and the NOP Connect digital ecosystem. These assets, which required significant time and capital to build, create a substantial competitive moat. The company is committed to continuously widening this moat through ongoing innovation and strategic investments.

    02

    New Service Offering for Workflow Efficiency

    Effective July 1, 2026, TransMedics launched a new service offering: donor and recipient clinical screening coordination services. This service aims to enable transplant programs to run more of their workflow efficiently on the TransMedics platform. The company is piloting this initiative with a major healthcare system in Boston, expecting it to streamline processes, enhance support for centers, and provide greater visibility into the national donor pool, ultimately driving more transplants.

    03

    Massive Kidney Transplant Opportunity

    The U.S. kidney transplant market presents a massive opportunity, with over 21,000 deceased kidney transplants annually and approximately 9,200 recovered kidneys in 2024 that were never transplanted due to cold storage limitations. OCS Kidney, currently under development on the next-gen Gen 3.0 platform, is designed to be the first portable normothermic oxygenated perfusion system to significantly reduce ischemia and reperfusion injury. It also aims to include online functional assessment capabilities, with the potential to increase donor kidney utilization and reduce delayed graft function (DGF), which affects 26-50% of recipients and incurs significant costs.

    04

    European Expansion and PAD Aviation Investment

    TransMedics is actively replicating its successful U.S. NOP and logistics model in Europe, beginning with Italy, where national reimbursement for machine perfusion and services is anticipated to take effect in late 2026 or early 2027. The strategic investment in PAD Aviation in Germany, closed on July 1, 2026, is a crucial step, providing the necessary aviation infrastructure and license to compete for transplant logistics tenders across Italy and other European countries. This expansion leverages existing capabilities to materially grow the addressable market and extend life-saving impact.

    05

    Next-Generation OCS Platform (Gen 3.0)

    The OCS Gen 3.0 platform represents a complete redesign of the OCS system, engineered to deliver significant operating leverage and supply chain independence. This next-gen platform is designed to be highly autonomous, incorporating cloud-based remote monitoring and control capabilities. Its development is critical for scaling clinical usage and supporting an operating capacity of 30,000 transplants and beyond globally by 2032, providing a foundation for future growth.

    06

    Growth-Oriented Capital Allocation

    TransMedics maintains a clear capital allocation priority focused on durable top-line growth ahead of near-term operating leverage. The company is funding four key growth initiatives—heart and lung expansion (ENHANCE/DENOVO), OCS Kidney development, international expansion, and the NextGen OCS platform—over the next 18 to 24 months. Management emphasizes its track record of outperforming growth expectations and delivering strong bottom-line performance, asserting that these investments are crucial for achieving over $2 billion in annual revenue by 2032.

    AI-generated summary of the company’s earnings call. Not investment advice.